These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7586338)

  • 1. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy.
    Waters D; Higginson L; Gladstone P; Boccuzzi SJ; Cook T; Lespérance J
    Circulation; 1995 Nov; 92(9):2404-10. PubMed ID: 7586338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group.
    Waters D; Lespérance J; Gladstone P; Boccuzzi SJ; Cook T; Hudgin R; Krip G; Higginson L
    Circulation; 1996 Aug; 94(4):614-21. PubMed ID: 8772679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
    Waters D; Higginson L; Gladstone P; Kimball B; Le May M; Boccuzzi SJ; Lespérance J
    Circulation; 1994 Mar; 89(3):959-68. PubMed ID: 8124836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
    Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
    Waters D; Higginson L; Gladstone P; Kimball B; LeMay M; Lespérance J
    Control Clin Trials; 1993 Feb; 14(1):45-74. PubMed ID: 8440094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT).
    Kleemann A; Eckert S; von Eckardstein A; Lepper W; Schernikau U; Gleichmann U; Hanrath P; Fleck E; Neiss A; Kerber S; Assmann G; Breithardt G;
    Eur Heart J; 1999 Oct; 20(19):1393-406. PubMed ID: 10487800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
    Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS).
    Lancet; 1994 Sep; 344(8923):633-8. PubMed ID: 7864934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
    Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
    Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
    Teo KK; Burton JR; Buller C; Plante S; Yokoyama S; Montague TJ
    Can J Cardiol; 1997 Jun; 13(6):591-9. PubMed ID: 9215232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
    Post Coronary Artery Bypass Graft Trial Investigators
    N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
    Bestehorn HP; Rensing UF; Roskamm H; Betz P; Benesch L; Schemeitat K; Blümchen G; Claus J; Mathes P; Kappenberger L; Wieland H; Neiss A
    Eur Heart J; 1997 Feb; 18(2):226-34. PubMed ID: 9043838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women.
    Clearfield M; Downs JR; Weis S; Whitney EJ; Kruyer W; Shapiro DR; Stein EA; Langendorfer A; Beere PA; Gotto AM
    J Womens Health Gend Based Med; 2001 Dec; 10(10):971-81. PubMed ID: 11788107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.
    Probstfield JL; Margitic SE; Byington RP; Espeland MA; Furberg CD
    Am J Cardiol; 1995 Sep; 76(9):47C-53C. PubMed ID: 7572686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.
    White CW; Gobel FL; Campeau L; Knatterud GL; Forman SA; Forrester JS; Geller NL; Herd JA; Hickey A; Hoogwerf BJ; Hunninghake DB; Rosenberg Y; Terrin ML;
    Circulation; 2001 Nov; 104(22):2660-5. PubMed ID: 11723015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.
    Kroon AA; Aengevaeren WR; van der Werf T; Uijen GJ; Reiber JH; Bruschke AV; Stalenhoef AF
    Circulation; 1996 May; 93(10):1826-35. PubMed ID: 8635262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression.
    Mack WJ; Krauss RM; Hodis HN
    Arterioscler Thromb Vasc Biol; 1996 May; 16(5):697-704. PubMed ID: 8963728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Downs JR; Beere PA; Whitney E; Clearfield M; Weis S; Rochen J; Stein EA; Shapiro DR; Langendorfer A; Gotto AM
    Am J Cardiol; 1997 Aug; 80(3):287-93. PubMed ID: 9264420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.